Navigation Links
WuXi PharmaTech Receives Award from BASF
Date:7/1/2009

SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"We had been looking for a good CRO collaboration partner for years, and today I think we have found one, a top-notch partner," Dr. Alfred Hackenberger, President of the Specialty Chemicals Research Division at BASF, commented at the award ceremony. "And I know that WuXi will continue to provide the same excellent service in the future."

"We are pleased to receive this award by BASF in recognition of the efforts of WuXi's talented team," commented Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We will continue to focus on customer service to earn the trust and support of our partners."

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... ROCKLAND, Mass. , April 16, 2015 /PRNewswire/ ... of Merck KGaA, Darmstadt, Germany ... Senior Vice President, Head of Global Clinical Development. ... development expertise, including experience in Oncology and Immunology. ... leadership ability, having served as a Vice President ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... personalized immune therapies for cancer, announced today that ... Immunotherapy Index (LCINDX), a professional index recently established ... within the biotechnology space.  The ... in the immunotherapy space, including 6 big pharma ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... Biopharmaceuticals (Nasdaq: KERX ) today announced completion ... its Phase 3 registration program of Zerenex™, the Company,s ... serum phosphorus levels, or hyperphosphatemia, in patients with end-stage ... registration program, which is being conducted pursuant to a ...
... NEW HAVEN, Conn., Sept. 19, 2011 The U.S. ... of allowance related to Cenestra Health,s high-purity omega-3 fatty ... claims cover a range of high-purity omega-3 formulations including ... Cenestra Health was issued U.S. Patent No. ...
... 16, 2011 Generex Biotechnology Corporation ( www.generex.com ... Napolii, from University Campus Bio-Medico in Rome, Italy, ... on Generex Oral-lyn™ buccal insulin spray on September ... Study of Diabetes (EASD) annual meeting in Lisbon, ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 2Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 4
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... by eating the leaves of an invasive tree that soaks ... down water loss in the Southwestern United States. Two ... U.S. Geological Survey and the U.S. Department of Agriculture, have ... result from using Asian beetles for the biological control of ...
... WEST LAFAYETTE, Ind. - A Purdue University scientist and ... improved plant growth regulators that are expected to be ... of horticulture, said the growth inhibitors block the transport ... the plant, controls growth processes. Current growth regulators that ...
... whose work has overtones of Indiana Jones as they ... that could become the source of life-saving new medicines, ... international agreement on biodiversity will affect their work. That,s ... News (C&EN), ACS,s weekly newsmagazine. C&EN Associate ...
Cached Biology News:Scientists study control of invasive tree in western US 2Scientists study control of invasive tree in western US 3New growth inhibitors more effective in plants, less toxic to people 2
Request Info...
Request Info...
FITC~Bovine Serum Albumin...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: